Evidence map›Paper›PMID 40677835›Full record

ArticleMolecular therapy. Methods & clinical development2025

Ubiquitination-targeted therapies improve BMD iPSC myogenic cell engraftment and dystrophin expression

Muchen Liu, Somik Chatterjee, Jianbo Wu, Zeinab Kashaniasl, Ashok Kumar, Chunru Lin, Radbod Darabi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Muchen LiuInstitute of Muscle Biology and Cachexia (IMBC), University of Houston, Houston, TX, USA.
Somik ChatterjeeInstitute of Muscle Biology and Cachexia (IMBC), University of Houston, Houston, TX, USA.
Jianbo WuInstitute of molecular medicine, University of Texas Health Science Center at Houston, TX 77030, USA.
Zeinab KashaniaslInstitute of Muscle Biology and Cachexia (IMBC), University of Houston, Houston, TX, USA.
Ashok KumarInstitute of Muscle Biology and Cachexia (IMBC), University of Houston, Houston, TX, USA.
Chunru LinDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Radbod DarabiInstitute of Muscle Biology and Cachexia (IMBC), University of Houston, Houston, TX, USA.

Funding

TWEAK/Fn14/UPR Signaling in Skeletal Muscle WastingR01AR081487 · NIAMS · UNIVERSITY OF HOUSTON · PI ASHOK KUMAR · 2023 to 2026
$2.1M
NIAMS NIH HHS R01 AR081487
6 · The paper itself

Abstract

Becker muscular dystrophy (BMD) is caused by in-frame mutations in dystrophin gene, leading to progressive muscle weakness, and cardiac and respiratory complications. Currently, there is no cure. We have recently identified the importance of poly-ubiquitination in regulating dystrophin stability through the binding of lncRNA H19 to the dystrophin C-terminal zinc-finger domain (ZNF), inhibiting TRIM63-mediated poly-ubiquitination. We also demonstrated that BMD mutations lead to conformational changes in ZNF domain, reduced lncRNA H19 binding and increased dystrophin ubiquitination. Here we used BMD iPSCs to investigate the

Indexed as

Becker muscular dystrophyBMDdystrophiniPSCsubiquitination

Identifiers

PMID40677835
PMCPMC12268038

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.